Atea Pharmaceuticals, Inc. (AVIR) vs Carlsmed, Inc. (CARL)

A side-by-side comparison of Atea Pharmaceuticals, Inc. and Carlsmed, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Atea Pharmaceuticals, Inc. logo
AVIR
Atea Pharmaceuticals, Inc.
$406M
$5.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Carlsmed, Inc. logo
CARL
Carlsmed, Inc.
$398M
$14.64HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AVIR vs CARL

growth of $100 · dividends reinvested · last 1y
AVIR +49.6% (+49.6%/yr)CARL +5.5% (+5.5%/yr)AVIR compounded faster over this window
100150Start $1002026$150$106
AVIR CARL

AVIR vs CARL: by the numbers

  • •AVIR is the larger company ($406M vs $398M market cap).
  • •Both run net losses; AVIR's is the smaller (0.00% vs -57.42% net margin).

Metrics side by side

Valuation

MetricAVIRCARL
P/S ratioN/A6.29
P/B ratio1.994.72

Profitability

MetricAVIRCARL
Gross margin0.00%76.63%
Operating margin0.00%-61.09%
Net margin0.00%-57.42%
ROE-80.96%-43.14%
ROIC-89.93%-36.54%

Growth (annualized)

MetricAVIRCARL
Total return CAGR (5Y)-34.44%N/A

Go deeper

Full AVIR analysisFull CARL analysisInteractive comparison tool

Dig into the metrics

Atea Pharmaceuticals ROECarlsmed ROEAtea Pharmaceuticals operating marginCarlsmed operating marginAtea Pharmaceuticals revenue growthCarlsmed revenue growthAtea Pharmaceuticals free cash flowCarlsmed free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.